낫적혈구병(Sickle Cell Disease)(소아청소년과)
빈혈 관리
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (새로운 창 열기)
Source: Lancet Haematol. 2023 ;10(4):e261-71.
Indexed: PubMed 36870358
DOI: 10.1016/S2352-3026(22)00405-7
Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (새로운 창 열기)
Source: Eur J Haematol 1996;56(5):326-8.
Indexed: PubMed 8641410
On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (새로운 창 열기)
Source: Acta Haematol 1995;94(3):128-34.
Indexed: PubMed 7502628
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (새로운 창 열기)
Source: Haematologica 2006;91(8):1076-83.
Indexed: PubMed 16885048
Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (새로운 창 열기)
Source: J Obstet Gynaecol 2007;27(1):82-3.
Indexed: PubMed 17365469
DOI: 10.1080/01443610601062739
The use of barbiturate coma as salvage therapy in a postoperative Jehovah's Witness patient with life-threatening anemia. (새로운 창 열기)
Source: Am Surg 2009;75(12):1175-8.
Indexed: PubMed 19999907